The US paused Johnson & Johnson's COVID-19 vaccine on April 13 over reports of blood clots.
The pause was lifted Friday after the CDC investigated the vaccine's side effects.
Now the CDC is investigating two more cases of blood clots linked to the vaccine.
The Centers for Disease Control and Prevention is investigating two new blood-clotting cases reported after people got the Johnson & Johnson COVID-19 vaccine.
A CDC spokesperson told Insider that the agency was investigating two "confirmed reports" since Friday of a man and a woman getting blood clots after receiving the shot.
Both people were under 60 years old, the CDC said. The spokesperson said that to protect the people's privacy, other details wouldn't be revealed.
The two new reports bring the total number of blood clots reported after the Johnson & Johnson vaccine to 17, the CDC said. More than 8 million doses have been administered in the US.
On Friday, the US said it was resuming its rollout of the Johnson & Johnson vaccine. Health officials had paused the rollout on April 13 as they investigated the reports of blood clots. The Food and Drug Administration added a warning to the vaccine about the risk of unusual blood clots in women under 50 years old.
Polling has indicated that public confidence in the Johnson & Johnson vaccine took a nosedive after the pause. In a recent survey from ABC News and Langer Research Associates, about 41% of respondents said they thought the vaccine was "very or somewhat unsafe" - about the same proportion of respondents who said they considered the vaccine "very or somewhat safe."
Over 70% of respondents said they considered the vaccines from Pfizer and Moderna safe. Unlike Moderna's and Pfizer's two-dose vaccines, Johnson & Johnson's vaccine is just one shot.
Experts have said that of the three COVID-19 vaccines available in the US, Johnson & Johnson's shot does the best job at protecting against virus variants in the real world.
This is a developing story. Please check back for more updates.
Read the original article on Business Insider